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 CLINICAL STUDY OF FEVER WITH THROMBOCYTOPENIA WITH 
SPECIAL REFERENCE TO INFECTIVE ETIOLOGY AND 
COMPLICATIONS ADMITTED TO GOVERNMENT ROYAPETTAH 
HOSPITAL, CHENNAI 
 
ABSTRACT 
 
BACKGROUND: 
                    Fever with thrombocytopenia is a common condition that is associated  
with an increased risk of morbidity and mortality. Infections like Malaria,        
Dengue, Leptospirosis, Typhoid, HIV & septicemia are some of the common   
causes of fever with thrombocytopenia. Therefore a well organized systemic    
approach that is carried out with an awareness of causes of fever with          
thrombocytopenia can shorten the duration of investigations and bring out    
diagnosis. Hence, a need for study to know the causes and complications of fever 
with thrombocytopenia.  
AIMS AND OBJECTIVES 
1) To study the etiology of short duration fever with thrombocytopenia 
2) To study the clinical presentation and the laboratory profile of patients 
presenting with fever and thrombocytopenia. 
3) To assess the correlation of severity of thrombocytopenia with the bleeding 
manifestation . 
MATERIALS AND METHODS :  
          This was a cross sectional study which included all new patients above 
18 years with fever (temperature > 99.9 F) and thrombocytopenia (platelet count 
less than 1,50,000cells/ cu.mm ) admitted to Government Royapettah hospital. The 
data of each patient was collected on a proforma specially designed for this study 
which includes demographic details, clinical features, past medical history, clinical 
and Lab values which will be analysed for statistical significance and correlation. 
 
RESULTS : 
             In our study the leading cause of febrile thrombocytopenia was malaria. 
The 2
nd
 leading cause of febrile thrombocytopenia was dengue fever. Typhoid 
fever accounted for 6% of cases. Patients in whom diagnosis could not be made 
was 16%. Among the 100 patients in the study group, the maximum number of 
patients (54%) had a platelet count between 50,000 to 100000. Platelet count less 
than 20000 were found in only three patients. Only 11% of patients had bleeding 
manifestations. A total of 9 patients had received transfusion of blood products.7 
patients had received fresh whole blood alone and 2 of them had been transfused 
both fresh whole blood and platelets. The two patients who had received platelet 
transfusion were having sepsis and malaria. 
 
CONCLUSION AND INTERPRETATION: 
1) Infections are one of the most common causes of thrombocytopenia. The 
leading cause of fever with thrombocytopenia in our study was Malaria. 2) In 
malarial infection, the most common species was Plasmodium vivax followed by 
Plasmodium falciparum. 3) Dengue fever was the second commonest cause of 
febrile thrombocytopenia. 4) There is no direct correlation between the severity of 
thrombocytopenia and the bleeding manifestation. 5) Bleeding manifestation was 
present only in 11% of patients in the study. So in majority of patients, the 
thrombocytopenia was transient and asymptomatic. 6) Prophylactic platelet 
transfusion may not be required in all cases of severe thrombocytopenia. It may be 
restricted to selected patients with bleeding manifestation or platelets 
<10,000/cumm which may indicate bone marrow compromise.7) Most of the 
patients in our study did not require platelet or blood transfusion and the platelet 
count significantly increased after the treatment of the underlying infection. 
 
KEYWORDS : 
Fever, thrombocytopenia, malaria, dengue, bleeding, platelet count, platelet 
transfusion  
 
  
INTRODUCTION 
              There is an alarming increase in the incidence of fever with 
thrombocytopenia. Routinely we come across many cases, both as inpatients 
and outpatients presenting with fever with thrombocytopenia. Infection is one 
of the common cause of thrombocytopenia. Thrombocytopenia in fever can 
predict the cause and thus helps in early diagnosis and treatment, preventing 
further fatal outcome associated with it. 
          Though patients can initially present with simple fever, in due      
      course it can lead to unpredictable outcomes including death at times, therefore    
      the aim of the study is to analyse the clinical profile of fever with  
      thrombocytopenia, as early diagnosis and timely intervention prevents adverse  
      outcomes and can save lives.                              
                    Fever with thrombocytopenia is a common condition that is associated  
      with an increased risk of morbidity and mortality.  Infections like Malaria,        
      Dengue, Leptospirosis, Typhoid, HIV & septicemia are some of the common   
      causes of fever with thrombocytopenia. Therefore a well organized systemic    
      approach that is carried out with an awareness of causes of fever with          
      thrombocytopenia can shorten the duration of investigations and bring out    
      diagnosis. Hence, a need for study to know the causes and complications of      
      fever with thrombocytopenia. 
 AIM OF THE STUDY 
1) To study the etiology of short duration fever with thrombocytopenia 
2) To study the clinical presentation and the laboratory profile of patients 
presenting with fever and thrombocytopenia. 
3) To assess the correlation of severity of thrombocytopenia with the 
bleeding manifestation . 
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
 
THROMBOCYTOPENIA IN MALARIA 
                         Thrombocytopenia is one of the most common complications of 
both Plasmodium vivax and Plasmodium falciparum malaria. It is pertinent that the 
finding of thrombocytopenia in patient, may be an indication for a thorough 
lookout into the blood smear to rule out malaria as the cause. This fact is especially 
important in the workup for thrombocytopenia in febrile patients.
 
                         Malaria affects almost all blood components and is a true 
haematological infectious disease. Anaemia and thrombocytopenia are the most 
frequent malaria-associated haematological complications (Wickramasinghe & 
Abdalla 2000)
1
 and have received more attention in the scientific literature due to 
their associated mortality.  
                         In the current field of Travel Medicine, the rapid increase in the 
number of people travelling to tropical areas has added a great challenge for 
malaria diagnosis because the thick blood smear (the standard diagnosis in 
endemic areas) has high specificity but only when performed by experienced 
microscopists.  
                         The presence of thrombocytopenia in acute febrile travellers 
returning from tropical areas has become a highly sensitive clinical marker for 
malaria diagnosis (D’Acremont et al. 2002)2. Another study has reported 60% 
sensitivity and 88% specificity of thrombocytopenia for malaria diagnosis in acute 
febrile patients (Lathia & Joshi 2004)
3
.  
                         The sensitivity of thrombocytopenia together with the acute febrile 
syndrome was 100% for malaria diagnosis, with a specificity of 70%, a positive 
predictive value of 86% and a negative predictive value of 100% (Patel et al.2004)
4 
                       In 2005, 138 of 684 (20.1%) malarial cases hospitalised in a tertiary 
care centre in Manaus had thrombocytopenia as the cause of admission, which 
corresponded to 6.8% of hospitalisations due to all causes in this reference 
institution (unpublished observations). Hospitalisation, however, does not add any 
benefit to the patient and because there is no evidence for any intervention, this 
simply increases public health costs in underdeveloped and under-resourced areas. 
                        Since the beginning of the 1970s, there have been reports proposing 
that malaria-associated thrombocytopenia is quite similar in Plasmodium  vivax 
and Plasmodium falciparum infections (Beale et al. 1972)
5
. However, more recent 
data in India has shown how thrombocytopenia exhibited a heightened frequency 
and severity among patients with P. vivax infection (Kochar et al. 2010)
6
. 
                        It is a general consensus that thrombocytopenia is very common in 
malaria and previously it was believed that it is more common in Falciparum 
malaria. Recent studies have shown that thrombocytopenia is equally or even more 
common in P. vivax malaria contrary to the popular belief that it may be observed 
in P. falciparum malaria. More recent data in India has shown how 
thrombocytopenia exhibited a heightened frequency and severity among patients 
with P. vivax infection. Thrombocytopenia was seen in 40-90 percent of patients 
infected with P. falciparum infection in
 
India. Maximum thrombocytopenia 
occurred on the fifth or sixth day of infection, and gradually returned to normal 
within 5-7 days after parasitemia ceased.
 
 
HOW LOW IS THE PLATELET COUNT IN MALARIA? 
                            In a systematic review of literature, platelet counts less than 
150,000/mm3 occurred in 24-94% in patients with acute malaria and this 
frequency was not different between the two major species that affected humans.  
                            Minor bleeding is mentioned in case reports of patients with 
Plasmodium vivax infection. The relatively lesser incidence of major bleeds may 
be explained by medullary compensation with the release of mega platelets in 
the peripheral circulation by megakaryocytes, thus maintaining a good primary 
haemostasis.  
 
MECHANISM OF THROMBOCYTOPENIA IN MALARIA : 
The speculated mechanisms leading to thrombocytopenia are:  
1) coagulation disturbances,  
2) splenomegaly,  
3) bone marrow alterations,  
4) antibody-mediated platelet destruction,  
5) oxidative stress and the role of platelets as cofactors in triggering severe 
malaria.  
1 ) Coagulation disturbance -   A study based on 31 American soldiers in 
Vietnam with chloroquine-resistant falciparum malaria noted the following 
changes in the acute phase of the disease using the same patients as their own 
controls during convalescence: decrease in the platelet count and prothrombim 
activation time, increase in the activated thromboplastin time, and reduction in 
factors V, VII and VIII with normal fibrinogen (Dennis et al. 1967)
7
.  
                              In Manaus, 2004, a study with falciparum and vivax patients 
demonstrated a negative correlation between platelet counts, thrombin-anti-
thrombin complex and D-dimers, suggesting that the activation of coagulation 
could be partially responsible for thrombocytopenia (Marques et al. 2005)
8
. 
2) Splenomegaly - The spleen in malaria has played a crucial role in the immune 
response against the parasite, as well as controlling parasitaemia due to the 
phagocytosis of parasitised red blood cells (RBCs) (Engwerda et al. 2005)
9
. Some 
data suggested that platelets were sequestered in the spleen during the acute 
infection (Skudowitz et al. 1973)
10
. 
3) Bone marrow alterations -  a “dysmegakaryopoiesis” was proposed, similar to 
what happened in the human malarial anaemia model, where dyserythropoiesis was 
triggered by cytokines (Menendez et al. 2000)
11
. In the few studies that examined 
the bone marrow for this purpose, megakaryocytic lineage was apparently 
preserved (Naveira 1970, Beale et al. 1972)
12
. Thrombopoietin indeed seems to rise 
during the acute disease even in the presence of liver compromise, suggesting that 
no bone marrow inhibition is seen (Kreil et al. 2000)
13
. Additional data from FBC 
samples in vivax patients showed that there is a significant negative correlation 
between platelet count and mean platelet volume (Lacerda 2007)
14
, suggesting that 
megakaryocytes are able to release mega platelets in the circulation to compensate 
for the low absolute number of platelets in the periphery. Similar results were 
shown in children with falciparum malaria (Maina et al. 2010)
15
. These mega 
platelets are probably able to sustain a good primary haemostasis that could 
explain the low frequency of severe bleeding in malarial patients.  
4) Antibody-mediated platelet destruction - There is evidence that platelet-
associated IgG (PAIgG) is increased in malaria and is associated with 
thrombocytopenia. During acute malaria, thrombocytopenia is most probably 
associated with the binding of parasite antigens to the surface of platelets to which 
antimalarial antibodies also bind, leading to the in situ formation of immune 
complexes (Kelton et al. 1983)
16
. 
                             Because the generation of immune complexes is proportional to 
the amount of available antigen, the negative correlation between platelet count 
and peripheral parasitaemia reported in many studies (Lacerda 2007, Silva 
2009)
17,18  
corroborates immune mechanisms as a potential mechanism of platelet 
destruction. 
5) Oxidative stress - Free radicals may play an important role in the platelet 
destruction in malarial infection. 
6) Platelet aggregation - platelets from patients with acute malaria are highly 
sensitive to adenosine diphosphate (ADP) addition in vitro (Essien & Ebhota 
1981)
19
, and it is believed that ADP release following haemolysis could contribute 
to higher platelet aggregation. 
 
 
The Relationship Between Thrombocytopenia And Severe Malaria  
                 Severe thrombocytopenia (platelet count under 50,000/mm3), despite 
not being considered severe malaria according to World Health Organization 
criteria (WHO 2010) due to the inability to cause death per se, has been 
occasionally associated with severity (Gerardin et al. 2002, Rogier et al. 2004)
20,21
.                                                        
                 17 patients from Manaus affected by any of the WHO malaria severity 
criteria with confirmed P. vivax monoinfection, 14 presented with 
thrombocytopenia, suggesting that this haematological complication can be 
explored as a marker of the severity for this species (Alexandre et al. 2010)
22
. 
                           From the case reports available, the association between severe 
cases with thrombocytopenia is evident. However, that can be due to bias 
publication, where prospective studies would be needed to validate this 
association. On the other hand, considering that many studies point to a clear 
negative correlation between platelet count and parasitaemia (Grynberg et al. 2007, 
Silva 2009)
23,24
, it should be investigated if thrombocytopenia could be used in the 
surveillance of drug resistance, where higher parasitaemias for prolonged periods 
are usually found. 
 
 
MANAGEMENT OF THROMBOCYTOPENIA IN MALARIA : 
               Data from experimental models are presented and, despite not being rare, 
there is no clear recommendation on the adequate management of this 
haematological complication.  
               In most cases, a conservative approach is adopted and platelet counts 
usually revert to normal ranges a few days after efficacious antimalarial treatment.  
More studies are needed to specifically clarify if thrombocytopenia is the cause or 
consequence of the clinical disease spectrum. 
                             Platelet transfusion has been widely followed, but with no con-
firmed efficacy. The indication of prophylactic platelet transfusion when platelet 
counts are under 10,000/mm3 probably applies only when the bone marrow is 
compromised and is not able to release efficacious platelets (Rebulla 2000). This 
does not seem to be the case in malaria. Keeping platelet counts between 50,000 
and 100,000/mm3 is a formal indication only in patients undergoing surgical 
procedures (Rebulla 2001)
25
. In a tertiary care centre in the Western Brazilian 
Amazon over a 12-month period, 10.4% (20/191) of patients who received platelet 
transfusion were diagnosed with vivax or falciparum malaria (Lacerda et al. 
2006)
26
. The dosage was usually below that recommended in the literature 
(Schlossberg & Herman 2003)
27
. In 40% of patients, the only justifications for 
transfusion were maintaining a platelet count below 10,000/mm3 and discrete 
bleeding. In a further 6% of patients, only a very low platelet count was described. 
In this group of 40% of patients, the alleged reason was minor bleeding despite 
having non-severe thrombocytopenia; in 33%, no indication was verified. These 
data point to the little existing evidence of the recommendations for platelet 
transfusion in these patients. The corrected count increment to evaluate transfusion 
efficacy was not calculated for any patient. The low efficacy of platelet transfusion 
in general is well described for several acute infectious diseases (de Paula et al. 
1993)
28
, probably due to peripheral immune mechanisms of destruction that do 
not spare the transfused platelets.  
                          Indications for platelet transfusion in cases when DIC is suspected 
and diagnosed, the formal clinical indication persists, as recommended elsewhere 
(Franchini 2005)
29
. Due to the impossibility of using frozen platelets in routine 
clinical practice, other platelet substitutes and preparations are being investigated 
(Blajchman 2003)
30
. Except in atypical cases of ITP with severe bleeding, there is 
no evidence for the use of human intravenous immunoglobulin, even in cases of 
severe thrombocytopenia (Lacerda et al. 2004)
31
. 
                   The use of corticoids has never been followed, probably due to the 
fact that the recovery of thrombocytopenia following antimalarial treatment is seen 
in almost all cases, with good prognosis for all species that infect humans (Lacerda 
2007)
32
 and with the lack of robust evidence of immune-mediated destruction of 
platelets as a major mechanism. It was also found that in patients with cerebral 
falciparum malaria, dexamethasone exacerbated the neurological symptoms and 
increased the frequency of gastrointestinal bleeding (Warrell et al. 1982, Hoffman 
et al. 1988)
33,34
. However, in none of these studies was platelet recovery analysed 
as a secondary endpoint.  
 
                        Immune modulators are also candidates in the adjuvant antimalarial 
therapy (Muniz-Junqueira et al. 2005, Mohanty et al. 2006)
35,36
, based on the drug-
induced inhibition of adhesion molecules in RBCs and platelets (Muniz-Junqueira 
2007)
37
. The exploration of drugs known by their anti-inflammatory effect, 
modulating TNF, e.g., pentoxyfylline and thalidomide, upon severe malaria, could 
not only contribute to the understanding of the mechanisms of severity but also 
clarify the association between platelets and severe disease. 
                            The frequency of thrombocytopenia (i.e., platelet count below 
150,000/mm3) in malarial infection ranges from 24-94% in the literature, despite 
the low occurrence of severe bleeding, even in the case of severe malaria. It is still 
unclear whether this haematological complication is more frequent in P. vivax or 
P. falciparum malaria. The clinical management of malarial thrombocytopenia is 
expectant and the level of evidence for platelet transfusion is insufficient to 
recommend this practice. It is not clear whether platelets are diminished during 
acute malarial infection as a consequence of the immune response to the parasite 
present or whether platelets are actually involved in the generation of severe 
disease. 
 
 
 
 
 
 
 
 
 
 
 
 
SYSTEMATIC REVIEW OF STUDIES,  
ESTIMATING THROMBOCYTOPENIA IN MALARIAL PATIENTS IN 
INDIA (2002-2011) 
 
REFERENCES TYPE OF 
PATIENTS 
AGE 
RANGE 
SPECIES N THROMBOCYTOPENIA 
% 
Mohapatra et al. 
(2002) 
Inpatients 
and 
outpatients 
15-60 y P.v. 110 3.6 (< 100,000) 
Jadhav et al. (2004) Inpatients 
and 
outpatients 
All ages P.v. 973 65 (50,000-150,000) 
Kumar and 
Shashirekha (2006) 
Inpatients 
and 
outpatients 
All ages P.v. 27 88.8 (< 150,000) 
Prasad et al. (2009) Inpatients < 5 y P.f. 40 85 (< 150,000) 
Kochar et al. (2010) Inpatients 
and 
outpatients 
All ages P.v./P.f. 
and mixed 
1,064 24.6 (< 150,000) 
George and 
Alexander (2010) 
Inpatients 18-66 y P.v. 30 93.3 (< 150,000) 
Srivastava et al. 
(2011) 
Inpatients All ages P.v. 50 82 (< 150,000) 
 
 COLLATED CASE REPORTS OF PLASMODIUM VIVAX-ASSOCIATED 
THROMBOCYTOPENIA IN INDIA (2002-2011) 
 
REFERENCES PLATELET 
COUNT 
(X 1,000/MM3) 
BLEEDING PLATELET 
TRANSFUSION 
OBSERVATION 
Makkar et al. (2002) 8 Gingival bleeding Yes - 
Aggarwal et al. (2005) 6 Petecchiae Yes - 
Katira and Shah (2006) 14-92 No Yes - 
Kaur et al. (2007) 30 No No Acute renal failure 
Kaur et al. (2007) 30 Petecchiae No Acute renal failure 
Vij et al. (2008) NA Gingival bleeding No NA 
Parakh et al. (2009) 5-42 Petecchiae No Cerebral malaria, 
shock and acute renal 
failure 
Thapa et al. (2009) 11 Petecchiae and 
mucosal bleeding 
Yes Hepatitis and shock 
Harish and Gupta 
(2009) 
1 Intracranial bleed No Seizures 
Bhatia and Bhatia 
(2010) 
NA Yes NA NA 
 
 
 
 
THROMBOCYTOPENIA IN DENGUE FEVER 
 
                            Dengue Haemorrhagic Fever is a probable case of dengue and 
haemorrhagic tendency evidenced by one or more of the following: 
1) Positive tourniquet test 
2) Petechiae, ecchymosis or purpura 
3) Bleeding from mucosa (mostly epistaxis or bleeding from 
    gums), injection sites or other sites 
4) Haematemesis or melena 
5) Thrombocytopaenia (platelets 100,000/cu.mm or less) and 
6) Evidence of plasma leakage due to increased capillary permeability manifested   
by one or more of the following: 
– A >20% rise in haemotocrit for age and sex 
– A >20% drop in haemotocrit following treatment with fluids as compared to 
baseline 
– Signs of plasma leakage (pleural effusion, ascites or hypoproteinaemia). 
                                Dengue Shock Syndrome (DSS) -   All the above criteria of 
DHF plus signs of circulatory failure manifested by rapid and weak pulse, narrow 
pulse pressure (< or equal to 20 mm Hg); hypotension for age, cold and clammy 
skin and restlessness. 
 CAUSE OF THROMBOCYTPENIA IN DENGUE: 
                          Although not fully elucidated, recent evidence indicates that 
severe Dengue viral  infections increase vascular permeability that  
leads to decreased intravascular  ﬂuid volume and consequent 
hemoconcentration and hypotension in infected patients. Another feature of 
Dengue viral infection is thrombocytopenia, which is common in both mild and 
severe diseases. 
                         Dengue virus  has been isolated from polymorphonuclear 
leukocytes, monocyte / macrophages, dendritic cells and others
38
 .It has also been 
detected in megakaryocyte progenitors and circulating platelets 
39,40,41 
These 
findings suggest that Dengue virus may induce thrombocytopenia via direct 
interactions with megakaryocytes and platelets. Dengue virus has also been shown 
to reduce circulating platelet counts independent of virus attachment or entry into 
platelets or their precursors. Thus, two mechanisms are probably involved in 
dengue-induced thrombocytopenia:
 
1) impaired thrombopoiesis and  
2) peripheral platelet destruction 
 
 1) IMPAIRED THROMBOPOIESIS 
                            Marrow suppression within 2–4 days of dengue viral infection 
can contribute to thrombocytopenia . Viral RNA has been isolated from bone 
marrow specimens of infected individuals, suggesting that dengue targets the 
marrow and hematopoietic system.
42  
Bone marrow studies also reveal diminished 
megakaryopoiesis during the onset of dengue infection and clinical recovery is 
associated with normal megakaryocyte topography and platelet counts 
43 
Suppression of megakaryopoiesis occurs either directly, due to infection and 
suppression of hematopoietic progenitor cells or indirectly, via impairment of 
stromal cells that function by altering the repertoire of cytokines in the bone 
marrow microenvironment. In regard to direct effects, Nakao et al. 
44  
demonstrated 
that Dengue virus- 4 propagates in human bone marrow progenitors in vitro and 
alters their proliferative capacity. Dengue viral infection suppresses proliferation of 
human cord blood progenitors and Dengue Virus -2 inhibits the differentiation of 
CD34+ progenitors into megakaryocytes, presumably by inducing apoptosis in 
infected cells
45,46
 
 
                               Together, these data support that DV is able to directly infect 
hematopoietic progenitors and suppress megakaryopoiesis and thrombopoiesis. 
Dengue virus can also infect stromal cells, which in turn suppresses hematopoiesis. 
Rothwell et al.
47 
infected long-term marrow cultures with Dengue Virus -2 and 
characterized the viral antigen-positive cells. This investigation demonstrated two 
types of stromal cells that were positive for viral antigens: adventitial reticular cells 
and bone marrow dendritic cells.  Altered cytokine production by infected stroma 
is the most probable mechanism of marrow suppression during DV infection. The 
in vitro findings described above and the hematological findings of leukopenia in 
conjunction with thrombocytopenia in dengue patients are used as argument in 
favor of dengue globally suppressing bone marrow hematopoiesis. 
48  
However, 
emerging evidence indicates that dengue infection also has extramedullary effects 
on circulating platelets. 
2) INCREASED PERIPHERAL DESTRUCTION 
a) Autoimmune-induced platelet activation and clearance 
b) Platelet–leukocyte and platelet–endothelial cell interactions 
c) Platelet dysfunction 
d) Direct infection 
e) Soluble mediators 
 
Autoimmune-induced platelet activation and clearance 
                             Several groups have put forth the autoimmune hypothesis, which 
postulates that host-generated anti-Dengue virus antibodies crossreact with 
platelets and facilitate their clearance 
49  
In support of this concept, serum from 
dengue patients can bind platelets and higher levels of antiplatelet IgM are 
observed in severe DV infections when compared to classical dengue fever
50
. 
Moreover, dengue patient serum or rabbit anti nonstructural protein-1 (NS1) 
induce complementmediated lysis in platelets
51,52
  which may contribute to the loss 
of circulating platelets during dengue illness. Autoantibodies directed against NS1 
target human platelets and fibrinogen and induce thrombocytopenia in mice
 53 
 
A molecular mimicry mechanism has been proposed in which the C-terminal 
region of NS1 shows sequence homology with integrins on the surface of platelets. 
 
              In clinical settings, increased levels of platelet-associated immunoglobulin 
(PAIgM or PAIgG) and phagocytosis of platelets by macrophages correlates with 
thrombocytopenia during the acute phase of secondary dengue infection 
54 
Similarly, anti-NS1 autoantibodies or pooled sera from dengue patients enhance 
the engagement of immunoglobulinopsonized platelets by macrophages.  
Platelet–leukocyte and platelet–endothelial cell interactions 
                           Similar to platelets, antibodies directed against Dengue Virus NS1 
crossreact and activate endothelial cells . Endothelial cells infected with Dengue 
Virus display high expression of E-selectin and support the adherence of platelets. 
Platelets that adhere to dengue-infected endothelial cells express surface P-selectin. 
Increased interactions of platelets with leukocytes and endothelium are probably 
contributors to the pathogenesis of dengue disease, including thrombocytopenia. 
Platelet dysfunction 
               There are a few studies examining platelet function in dengue disease. 
Among these, it has been shown that dengue serum abnormally activates platelets 
and inhibits platelet aggregation . 
Direct infection 
                        Recent studies indicate that dengue virus directly interacts and 
activates platelets. DV induces morphological changes in normal platelets typical 
of activation, including the presence of filopodia and degranulation . In parallel, 
Dengue virus increases the expression of surface P-selectin and fibrinogen binding 
. Dengue viral RNA and viral-like particles have also been detected in platelets of 
affected patients.  
Soluble mediators 
                        Key mediators that activate platelets and induce thrombocytopenia 
are often present in dengue infection. Monocytes from a donor infected with 
Dengue virus-1 respond to a second hit of dengue virus-2 by generating Platelet 
Activating Factor (PAF), a lipid mediator that augments platelet aggregation. This 
observation is in agreement with others demonstrating that thrombocytopenia and 
disease severity is reduced in mice lacking the PAF receptor (PAFr). Fibrin 
degradation products (D-dimers) and thrombin/ antithrombin complexes are 
typically increased after dengue infection
55
 Von Willebrand factor is likewise 
increased, creating a milieu for enhanced platelet activation. An array of cytokines, 
such as tumor necrosis factor-a (TNF-a) and interleukin-1b (IL-1b) are also 
produced during dengue infection. These cytokines have been linked to the onset 
and regulation of thrombosis and hemostasis and it has been demonstrated that 
increased TNF-a and IL-1 b in dengue patients correlates with thrombocytopenia . 
TARGETING PLATELETS IN THE TREATMENT OF DENGUE 
INFECTION 
                           Although thrombocytopenia is frequently observed in patients 
with dengue, severe bleeding is rare. When it occurs, however, excessive bleeding 
is associated with a high lethality. It is controversial as to whether the intensity of 
thrombocytopenia predicts bleeding risk in dengue patients; nonetheless, it is well 
accepted that severe thrombocytopenia associates with hemorrhagic 
manifestations. In addition, it is probable that other factors, such as disseminated 
intravascular coagulation (DIC), hepatic impairment and/or vascular dysfunction, 
act in concert with thrombocytopenia to induce bleeding.  
                         Platelet transfusion has been used as a strategy for the prevention 
or treatment of severe bleeding in patients with dengue. However, recent WHO 
guidelines do not recommend platelet transfusion for hemodynamically stable 
patients with thrombocytopenia. Even in patients who exhibit severe bleeding 
and hemodynamic instability, transfusion of platelets is only considered with 
restrictions. Importantly, these recommendations are based solely on the opinions 
of experts or small observational studies rather than randomized clinical trials. 
                          Other treatments considered for dengue-induced thrombocytopenia 
are anti-D immune globulin (anti-D) and PAFr antagonists.
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Of these, anti-D has 
shown promise in the treatment of severe thrombocytopenia in DHF patients while 
a PAFr antagonist relieved thrombocytopenia in a mouse model of dengue 
infection . By contrast, IVIG did not hasten the recovery of thrombocytopenia in 
dengue patients with secondary DV infection. Moving forward, it will be important 
to consider nontraditional roles of platelets in the treatment of dengue. This 
includes their role in regulating viral infection and replication, inflammation and 
vascular integrity, which may identify new molecular targets for the treatment of 
dengue infection 
 
Schematic representation of two major mechanisms involved in dengue-induced 
thrombocytopenia: bone marrow suppression and peripheral platelet destruction. 
  
THROMBOCYTOPENIA IN HIV INFECTION 
                       Thrombocytopenia in HIV was first described in 1982. The 
prevalence is more or less 40%, depending on which literature is quoted. 
Thrombocytopenia is associated with increased morbidity and mortality, 
accelerated deterioration in CD4 counts and accelerated progression to full-blown 
AIDS. In a meta-analysis of 5 trials involving > 3 000 patients, both treatment-
naïve and treatment-experienced patients, thrombocytopenia was found to be one 
of 8 factors that correlated with a poorer prognosis and more rapid progression to 
full-blown AIDS in spite of antiretroviral treatment. 
                           A recent study showed that platelets have the ability to ‘engulf ' 
the Human immunodeficiency virus and Staphylococcus aureus – perhaps another 
reason why thrombocytopenia is prone to a more rapid acceleration of disease. 
Severe thrombocytopenia also limits one’s treatment options, as many drugs cause 
bone marrow suppression and peripheral platelet consumption. HIV enters the 
megakaryocytes and platelets via the CXCR4 receptors. Once the virus is in the 
megakaryocyte it starts to cause havoc, as shown by the change 
in megakaryocyte morphology  
                         Thrombocytopenia early on in HIV is mainly due to peripheral 
destruction, while later on in the advanced stage (AIDS) it is more likely to be due 
to decreased production. In fact, CD4 counts above 200 are associated with 
increased peripheral destruction while thrombocytopenia in CD4 counts of < 200 is 
associated with decreased platelet production. 
                         In one study the authors found a 3-fold increase in megakaryocytes 
in patients with HIV. However, there was no increase in the mean platelet mass, 
suggesting the presence of dysmegakaryopoiesis. This suggests that 
thrombocytopenia in HIV is multifactorial because of: 
• direct HIV infection of the megakaryocyte, causing apoptosis 
• dysmegakaryopoiesis, abnormal and dysfunctional production of megakaryocytes 
and platelets 
• peripheral destruction of platelets due to cross-reactivity of HIV Abs. 
Who to treat 
There are no standardized guidelines in the treatment of HIV-induced 
thrombocytopenia. 
The generally accepted guideline is to treat when there are < 30 000 platelets 
or < 50 000 if the patient is on warfarin or a haemophiliac. One must still 
remember that thrombocytopenia correlates with a poorer outcome and 
accelerated HIV course and at least a 2- fold increase in mortality. In opposition 
to this, treatment of thrombocytopenia is immunosuppressive in its nature and 
therefore should be given in conjunction with antiretrovirals.  A platelet count of 
50000 post-treatment is quite acceptable for protection against bleeding, but still 
does predict a poorer outcome with regards to mortality and morbidity. 
 
Therefore thrombocytopenia occurs as a result of: 
• increased peripheral destruction or 
• increased peripheral sequestration or 
• decreased production or 
• a combination of the above. 
Approach to management 
Do a bone marrow biopsy, to asses megakaryocyte numbers and morphology. 
One can then easily exclude granulomas, Kaposi’s sarcoma and lymphoma or even 
fibrosis in the marrow. Once the decision is made to treat, then the difficulty is 
deciding how to treat. 
Steroids 
                       A dose of 1 mg/kg/day prednisone should be started as a first-line 
therapy. Monitor the platelet counts regularly and be alert for opportunistic 
infections. If no response is seen within a 2-week period, one can try a higher 
dosage of 2 mg/kg/day. This is the dosage used in the HIV-negative cohort. These 
patients should be monitored carefully and be on antiretrovirals. Patient should not 
stay on high-dosage therapy for more than a month. If no response or a nominal 
response is seen, it should be considered as treatment failure and alternative 
treatment given. Prednisone does not stimulate viral replication but does however 
accelerate the course of Kaposi’s sarcoma. 
Intravenous immunoglobulin 
                        Intravenous immunoglobulin (IVIG) is effective in raising a 
patient’s platelet counts. However, it is not cheap and results can be short lasting. It 
is not a cost-effective way of maintaining a platelet count and should only be used 
in chronic cases as a last resort. In the acute setting it is good for raising counts 
prior to a splenectomy or if patients have severe or uncontrollable haemorrhage. 
This would then be used in conjunction with platelet transfusions. The exact 
mechanisms of action are not entirely understood – suffice to say that excessive 
immunoglobulin (Ig) overwhelms the immune system and stimulates the 
suppressor B cells to suppress endogenous Ig production. The IVIG also blocks the 
Fc receptors in the spleen and macrophages, thereby limiting their platelet-
destroying function. The dosage of the IVIG can differ from 0.5 g/kg to 2 g/kg 
either as a bolus but mostly given over 2 - 5 days. The cost and availability of 
IVIG are the most limiting factors. 
 
 Anti-D 
                          The anti-rhesus globulin can also be used with varying success. 
This should not be used in patients who are Rh+ as it may cause haemolysis. It can 
however be used if the patient has a normal haemoglobin. Its effects, if there is 
going to be a response, are said to be longer lasting than IVIG. 
 
Splenectomy 
                        Splenectomy is the usual 2nd-line of therapy with the HIV-negative 
cohort.There were concerns initially that it would accelerate the course of HIV. 
This was before antiretroviral therapy was commonly available. At the moment, 
besides the concerns of infections from capsulated organisms and malaria, 
splenectomy may be a good alternative. The literature has shown splenectomy to 
attenuate immune reconstitution syndrome and has shown to produce patients with 
a higher CD4 and CD8 counts along with a slower progression to AIDS. Splenic 
irradiation is of no value in this situation. 
Megestrol acetate 
                     This drug was initially used to treat cachexia and anorexia in HIV. It 
is known to block the Fc receptors in macrophages. Trials have shown that 
megestrol acetate (MA) increases peripheral platelet counts and improves platelet 
survival. There were no improvements in body mass index (BMI), peripheral CD4 
counts or viral loads. Danazol is still of value in idiopathic thrombocytopenic 
purpura, even in HIVinduced ITP. 
 
Transfusions 
                Transfusions have a transient effect, they are expensive and should be 
limited to emergencies and during surgery. Normally they should be given with 
IVIG to have a longer lasting effect. Transfusions have other sideeffects e.g. 
transfusion reactions, infections and transfusion-related acute lung injury (TRALI). 
Multiple transfusions are known to decrease immunity and stimulate HIV-1 
expression. 
Novel therapies 
                     These are still in experimental phases but include entities such as 
recombinant thrombopoietin, alpha interferon and IL-6, IL-3, AND IL-11.  
 
THROMBOCYTOPENIA IN LEPTOSPIROSIS 
 
                        Leptospirosis is a zoonosis with protean manifestations. The 
commonly identified complications of acute renal failure and jaundice have been 
widely described and reviewed in a considerable number of literatures. Severe 
cases of leptospirosis often presents not only with renal failure and jaundice, but 
also with other organ involvement including myocarditis, aseptic meningitis, and 
hemorrhagic diathesis. 
                       The hemorrhagic manifestations of leptospirosis occur in many 
ways. Pulmonary hemorrhage is a dreaded complication because it is associated 
with a high mortality rate.  In 1984, an epidemic of pulmonary hemorrhagic fever 
occurred in Korea. Extensive investigations were undertaken to determine the 
cause, including clinical, pathological and epidemiological studies of all possible 
causative agents. The investigations finally came up with leptospirosis as the 
culprit.  
                  In the year 1995, an outbreak of an acute febrile illness and pulmonary 
hemorrhage occurred during the period of October to November.  More than 2000 
persons were affected and at least 40 patients died from acute pulmonary 
hemorrhage and respiratory insufficiency. The initial considerations were dengue 
hemorrhagic fever and the hantavirus pulmonary syndrome, but serologic tests 
detected anti-leptospiral antibodies and immunohistochemical staining of tissues 
from fatal cases demonstrated leptospiral antigens present in various organs. 
Together with myocarditis, pulmonary hemorrhage and GI bleeding were 
identified as common complications leading to death. 
                  Thrombocytopenia in leptospirosis has received little attention. Most 
studies on the pathogenesis of leptospirosis focused on renal failure and jaundice. 
With the outbreaks of pulmonary hemorrhage in association with leptospirosis, our 
focus should shift to the mechanisms causing the bleeding diathesis in this 
particular disease. Thrombocytopenia is thought to be fleeting, mild and rare. 
However, reviews reported increasing prevalence of thrombocytopenia. Some 
authors postulated that this could possibly be attributed to  
1) disseminated intravascular coagulation (DIC) or a toxin or cytotoxin mediated 
mechanism;  
2) as a direct complication of leptospiral vasculitis as a general phenomenon of 
septicemia, or due to an undetected platelet antibody.  
Whether either of these mechanisms is operating alone or in combination is 
uncertain and merits extensive investigation. 
It is important for clinicians to be aware and to recognize the various ways in 
which leptospirosis can present. Although classically occurring as an acute febrile 
illness with renal failure and jaundice, the other less common manifestations may 
predominate. The changing pattern of the virulence of the disease could have been 
better explained by identifying the serovars involved. It has been speculated that a 
new strain of leptospires may be responsible for the more severe presentation in 
some patients. Our poor yield in culture studies for Leptospira, and the 
unavailability of specific antigens for the different serovars makes this difficult. 
                           Thrombocytopenia can occur in mild to moderate to severe forms; 
majority of the platelet counts were between 20,000 and 80,000.Thrombocytopenia 
in leptospirosis was also associated with increased number of fatal complications. 
The presence of thrombocytopenia indicated a more severe form of leptospirosis.. 
Mortality rate was higher in the thrombocytopenic group compared to the 
nonthrombocytopenic group 
 
THROMBOCYTOPENIA IN TYPHOID FEVER 
                                The hematological changes are common in typhoid fever and 
these include anemia, leucopoenia, eosinophilia, thrombocytopenia and sub clinical 
disseminated intravascular coagulation. Thrombocytopenia is a common finding 
amongst patients presenting with typhoid fever as it causes reversible bone marrow 
suppression.  Bone marrow suppression and hemophagocytosis are considered to 
be an important mechanism in producing hematological changes.
57 
                                 Many cases of typhoid fever have peripheral blood cytopenias 
that were not concurrent bone marrow suppression, suggesting a peripheral 
mechanism responsible for the blood dyscrasia in those cases
58
. However, in other 
studies the patients suffering from typhoid fever with pancytopenia, bone marrow 
examination revealed extensive haemophagocytosis which possibly contributed to 
the pancytopenia.  The term haemophagocytosis describes the pathological finding 
of activated macrophages and engulfing erythrocytes, leucocytes, platelets, and 
their precursors cells.
59 
 
 
THROMBOCYTOPENIA IN SEPSIS : 
                  Thrombocytopenia is a frequent finding in critical illness and is 
commonly employed in clinical trials of severe sepsis therapies as a marker of 
hematologic organ dysfunction. 
                   In the ICU setting platelets <1,00,000/mm
3 
are identified in 20-40% of 
patients. In a study of ICU patients sepsis was identified as a major risk factor for 
thrombocytopenia. 
Mechanism: 
Sepsis induced thrombocytopenia is multifactorial in origin.  
1) In experimental models of sepsis platelets adhere to activated endothelium in 
multiple organs. Following adhesion the activated platelets may either dislodge and 
return to the circulation or release their granule contents and undergo irreversible 
aggregation with vicious metamorphosis.  
2) Inflammatory mediators and bacterial products such as endotoxins can 
contribute to sepsis induced thrombocytopenia by enhancing platelet reactivity and 
adhesivity.  
3) Phagocytosis of platelets by reticuloendothelial elements may also contribute to 
cytopenias in sepsis.  
4) Immune mechanisms may contribute to sepsis-induced thrombocytopenia. 
Nonspecific platelet-associated antibodies can be detected in up to 30% of ICU 
patients. In these patients, nonpathogenic IgG presumably binds to bacterial 
products on the surface of platelets, to an altered platelet surface, or as immune 
complexes. A subset of patients with platelet-associated antibodies have 
autoantibodies directed against glycoprotein IIb/IIIa. These antibodies have been 
implicated in the pathogenesis of immune thrombocytopenic purpura and, although 
not proved, may play a role in mediating sepsis-induced thrombocytopenia. 
                      Microscopy of bone marrow in patients with sepsis often 
demonstrated hemophagocytic histiocytes. In a prospective study of 50 patients 
with sepsis hemophagocytosis was identified in 32 patients (64%). This process 
appears to be a function of elevated levels of macrophage colony stimulated factors 
and is correlated with the presence and extent of multiorgan dysfunction. In some 
patientswith sepsis antibodies to specific antiplatet antigens such as GPIIb/IIIa and 
GP Ib/IX have been detected. 
                             The acute phase response is often characterized by increased 
platelet counts (thrombocytosis). However, patients who are admitted to the ICU 
with or without underlying sepsis are more commonly diagnosed as 
thrombocytopenia. Thrombocytopenia occurs in up to 20% of medical ICU and 
35% of surgical ICU admissions
61,62,63
. Sepsis is a clear risk factor for 
thrombocytopenia, with an estimated incidence of 35% to 59%
64,65
. In addition, 
there is an inverse relationship between the severity of sepsis and the platelet 
count. 
                              In a prospective study of critically ill patients with 
thrombocytopenia only 34% had a diagnosis of DIC. Secondary consumptive 
thrombocytopenia and DIC represent an extreme in the continuum of hemostatic 
abnormalities. In addition to sepsis-related mechanisms, other causes of 
thrombocytopenia should be considered in the critically ill patient. For example, 
thrombocytopenia may occur as a complication of heparin therapy. Other types of 
drug induced thrombocytopenia are rare in the ICU setting. Dilutional 
thrombocytopenia may occur in patients with trauma or those who have undergone 
complicated surgery. Preexisting underlying disease, including cancer and immune 
thrombocytopenic purpura, may also contribute to a low platelet count. Given the 
inverse correlation between platelet count and mortality and the proposed 
association of platelet activation with tissue injury and organ dysfunction, the 
development of thrombocytopenia in the patient with sepsis is best regarded as 
maladaptive. 
 
Clinical Manifestations and Diagnosis 
                           Thrombocytopenia is a common cause of bleeding in the ICU 
setting. Patients with thrombocytopenia may have petechiae, purpura, bruising, or 
bleeding. Thrombocytopenia is diagnosed on the basis of the complete blood cell 
count. A peripheral smear may show evidence of platelet clumping. If that is the 
case, the platelet count should be remeasured in blood withdrawn into a non-EDTA 
containing tube. If the thrombocytopenia is associated with consumptive 
coagulopathy, the DIC screen may be abnormal, and the peripheral smear may 
show schistocytes. Although patients with sepsis may have increased platelet-
associated IgG, testing for this gives nonspecific results and does not help to guide 
therapy. 
Prognosis  
                        Thrombocytopenia is a predictor of mortality in patients in the ICU 
and in patients with severe sepsis
65,66
. The degree and duration of 
thrombocytopenia, as well as the net change in the platelet count, are important 
determinants of survival
67,68,69
. Interestingly, once the platelet count decreases 
lower than 100 x10
9
/L, mortality continues to increase, whereas the risk of 
bleeding does not increase. 
Treatment 
                             Patients with severe thrombocytopenia should be treated with 
platelet transfusions. Although guidelines for prophylactic transfusions in patients 
with chemotherapy-induced thrombocytopenia have been established, the threshold 
for transfusions for the thrombocytopenic patient with sepsis is not as clear. In the 
absence of confounding factors, patients should probably receive transfusions 
when the platelet count is less than 10000 – 150000/cumm. If the patient has 
concomitant coagulopathy (eg. liver disease), active bleeding, or platelet 
dysfunction (eg, uremia), the transfusion threshold should be increased. 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS: 
Study group :     
 All new patients above 18 years with fever (temperature > 99.9 F) and 
thrombocytopenia  (platelet count less than 1,50,000cells/ cu.mm )                      
admitted to Government Royapettah hospital 
Study design   :  Cross-Sectional study 
Place of study                       :  Government Royapettah Hospital 
Duration of study             : 6 months (March-August 2013) 
This study protocol was approved by the Ethical committee for research 
studies of Government Kilpauk Medical College Hospital, Chennai. 
Inclusion criteria : 
 All new patients above 18 years with fever ( temperature > 99.9 F ) and 
thrombocytopenia ( platelet count less than 1,50,000 cells/ cu.mm )  
Exclusion criteria : 
 Patients presenting with thrombocytopenia without fever 
 Diagnosed cases of Thrombocytopenic purpura on treatment 
 Patients with thrombocytopenia already diagnosed to have haematological 
disorder / malignancy , on treatment with  chemotherapy and other 
immunosuppresants  
 Diagnosed cases of platelet disorders and dysfunction 
 Patients on treatment with antiplatelet drugs and other drugs causing 
thrombocytopenia 
 Patients with cirrhosis and chronic liver disease  
 
METHODOLOGY: 
                  Once the patients are admitted with fever and those who have 
thrombocytopenia confirmed by complete blood count, a careful history will be 
recorded, general physical examination and detailed examination of various 
systems will be done. Routine investigations and specific investigations will be 
done as and when indicated. Details of history, general physical examination and 
laboratory and technical investigation reports will be noted down from time to 
time. 
 
 
 STUDY  TOOLS- 
                                    Questionnair                                                                                                                       
                                    Case sheets of patients 
                                    Temperature charts 
 VARIABLES                                                                                      
 Age group   -       four groups were made, below 20yrs, 20-40yrs ,40 – 60yrs   
                             and above 60 yrs 
 Sex               -       male and female 
 Fever duration  
 Chills and rigor- if present or not 
 Joint pain- recorded from the history 
 Head ache- the duration and episodes of headache assessed, and considered 
present or absent 
 Vomiting- the number of episodes of vomiting and number of days for 
which it persists are considered, 2-4 episodes for more than 2 days are 
considered as vomiting present. Rest as no vomiting 
 Myalgia-those having muscle pain for more than 2 days, without any relief 
even with rest are considered as myalgia present 
 Organomegaly – this includes both hepatomegaly and spleenomegaly, it is 
assessed by the clinical examination of the patient, the clinical records and 
the ultrasonogram results. 
 Bleeding – any bleeding manifestation like purpura, petechiae, hematuria, 
malena, hematemesis was considered as positive 
 Anemia – less than 10 gm hemoglobin were considered as having anemia 
 Thrombocytopenia-  A count below 1,50,000/cumm was considered to 
have thrombocytopenia 
 Creatinine – a creatinine valve > 1 mg/dl was considered as renal 
involvement 
 ALT/AST – values more than 40 IU/L was considered elevated for each 
 Serum bilirubin – more than 1mg/dl was considered as hyperbilirubinemia 
 Peripheral smear study or QBC for malaria – was considered diagnostic 
for malaria 
 Widal test or blood culture for Salmonella typhi -  was considered 
diagnostic for enteric fever 
 IgM dengue – was considered diagnostic for dengue fever 
 IgM for leptospirosis or MAT – was considered diagnostic for 
leptospirosis 
 ELISA/Western blot – was taken as positive for HIV 
 patients in whom the diagnosis could not be made even after all the above  
mentioned investigations were categorised as having unspecified viral fever. 
 
    Once the specific diagnosis was reached, patients were treated specifically 
and symptomatically. Data was collected by using pre-tested proforma meeting the 
objectives of the study. The data collected would be transferred in to a Master 
Chart, which was then subjected for statistical analysis. 
Data collection: 
The data of each patient was collected on a proforma specially designed for 
this study and which includes demographic details, clinical features, past medical 
history, clinical and Lab values which was analysed for statistical significance and 
correlation. 
STATISTICAL ANALYSIS 
Data was entered in Windows Excel format. Frequency tables and measures 
of central tendency (mean) and measures of dispersion (Standard Deviation) were 
calculated by using the statistical package SPSS- 20 
OBSERVATION AND RESULTS 
 
1.DISTRIBUTION OF THE PLATELET COUNT IN THE STUDY 
POPULATION  
 
 
 
 
 
                   
                     Table 1. showing the distribution of platelet count in the study population  
 
Among the 100 patients in the study group, the maximum number of patients (54%) had a 
platelet count between 50,000 to 100000. 
Platelet count less than 20000 were found in only three patients. 
 
Fig.1. A pie diagram showing the distribution of platelet count in the study population 
Platelet Count
100001-150000
50001-100000
20001-50000
< 20000
PLATELET COUNT FREQUENCY PERCENT 
< 20000 3 3.0 
20001-50000 10 10.0 
50001-100000 54 54.0 
100001-150000 33 33.0 
2.DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO 
DIAGNOSIS AND  PLATELET COUNT 
 
    
Table 2. showing the distribution of study population according to diagnosis and platelet count 
 
 
 
 
 
DIAGNOSIS 
  
 
 
PLATELET COUNT 
TOTAL 
  < 20000 20001-50000 50001-100000 
100001-
150000 
Malaria 
  
  
Count 
1 4 24 13 42 
% within Diagnosis 2.4% 9.5% 57.1% 31.0% 100.0% 
  
Dengue 
  
Count 1 3 14 9 27 
% within Diagnosis 3.7% 11.1% 51.9% 33.3% 100.0% 
  
Typhoid 
Count 
0 0 5 1 6 
% within Diagnosis 
.0% .0% 83.3% 16.7% 100.0% 
  
Leptospirosis 
Count 0 0 2 3 5 
% within Diagnosis .0% .0% 40.0% 60.0% 100.0% 
  
Sepsis 
Count 0 2 1 0 3 
% within Diagnosis 
.0% 66.7% 33.3% .0% 100.0% 
  
Unspecified viral 
fever 
  
Count 
0 1 8 7 16 
 
% within Diagnosis .0% 6.3% 50.0% 43.8% 100.0% 
  
HIV 
  
Count 1 0 0 0 1 
% within Diagnosis 
100.0% .0% .0% .0% 100.0% 
Out of 100 patients, a definitive diagnosis was made in 84 patients.  
Among them, the leading cause of febrile thrombocytopenia in this study was 
MALARIA (42 cases). 
The second most common cause was DENGUE FEVER accounting for 27 cases. 
It was followed by  
UNSPECIFIED VIRAL FEVER (16 cases),  
TYPHOID (6 cases),  
LEPTOSPIROSIS (5 cases),  
SEPSIS (3 cases), and  
HIV (1 case) in that order. 
 
Only three patients were having platelet counts less than 20,000 in this study. They 
were caused by malaria, dengue fever and HIV each.  
The maximal frequency of platelet count in malaria, dengue, typhoid, sepsis and 
unspecified viral fever were in the range of 50000-100000 /cumm. 
  
Fig. 2. showing the distribution of study population according to diagnosis and platelet count 
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3.DISTRIBUTION OF THE STUDY POPULATION ACCORDING TO THE 
BLEEDING MANIFESTATION 
 
 
 
      DIAGNOSIS 
  
  
  
BLEEDING 
MANIFESTATION 
 
TOTAL 
  Yes No 
Malaria 
  
Count 5 37 42 
% within Diagnosis 11.9% 88.1% 100.0% 
  
Dengue 
  
Count 1 26 27 
% within Diagnosis 3.7% 96.3% 100.0% 
  
Typhoid 
  
Count 0 6 6 
% within Diagnosis  0% 100.0% 100.0% 
  
Leptospirosis 
  
Count 1 4 5 
% within Diagnosis 20.0% 80.0% 100.0% 
  
Sepsis 
  
Count 2 1 3 
% within Diagnosis 66.7% 33.3% 100.0% 
 
Unspecified viral 
fever 
Count 2 14 16 
% within Diagnosis 12.5% 87.5% 100.0% 
  
HIV 
  
Count 0 1 1 
% within Diagnosis .0% 100.0% 100.0% 
Total 
  
 
Count 11 89 100 
% within Diagnosis 11.0% 89.0% 100.0% 
 
Table 3. showing the distribution of study population according to bleeding manifestation 
 
 
 
A total number of 11 patients had various bleeding manifestations out of the 100 
study population. 
5 out of 42 patients with malaria had shown bleeding manifestation (11.9%)   
1 out of 27 patients with dengue fever had shown bleeding manifestation (3.7%) 
2 out of 3 patients with sepsis had bleeding manifestations (66.7%) 
1 out of 5 patients with leptospirosis had bleeding manifestation  (20%) 
In the unspecified viral fever group, 2 out of 16 patients had bleeding 
manifestation (12.5%) 
 
Fig.3.1. showing the distribution of study population according to bleeding manifestation 
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 Fig.3.2.  showing the distribution of study population according to bleeding manifestation 
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4.AGEWISE DISTRIBUTION OF STUDY POPULATION 
 
 
    DIAGNOSIS 
  
AGE GROUP IN YEARS  
TOTAL 
  < 20 21-39 40-59 > 60 
Malaria 8 15 12 7 42 
Dengue 2 13 11 1 27 
Typhoid 3 3 0 0 6 
Leptospirosis 2 1 1 1 5 
Sepsis 0 0 3 0 3 
Unspecified viral   
fever 
3 5 4 4 16 
HIV 0 0 0 1 1 
Total 18 37 31 14 100 
 
Table 4. showing age wise distribution of study population  
 Fig. 4. showing age wise distribution of study population 
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5.DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH  
CHILLS AND RIGORS 
 
 
Table 5. showing distribution of study population associated with chills and rigors 
 
71 out of 100 patients had fever associated with chills and rigors.  
32 out of this 71 patients were diagnosed with malaria.  
16 patients with dengue fever, 4 patients with typhoid fever, 5 patients with 
leptospirosis and 14 patients with unspecified viral fever were having fever 
associated with chills and rigors. 
 
DIAGNOSIS 
  
  
  
CHILLS & RIGORS  
TOTAL 
  
Yes No 
Malaria Count 32 10 42 
% within Diagnosis 76.2% 23.8% 100.0% 
  
Dengu 
Count 16 11 27 
% within Diagnosis 59.3% 40.7% 100.0% 
  
Typhoid 
Count 4 2 6 
% within Diagnosis 66.7% 33.3% 100.0% 
  
Leptospirosis 
Count 5 0 5 
% within Diagnosis 100.0% .0% 100.0% 
  
Sepsis 
Count 0 3 3 
% within Diagnosis .0% 100.0% 100.0% 
Unspecified viral 
fever 
Count 14 2 16 
% within Diagnosis 87.5% 12.5% 100.0% 
  
HIV 
Count 0 1 1 
% within Diagnosis .0% 100.0% 100.0% 
Total Count 71 29 100 
% within Diagnosis 71.0% 29.0% 100.0% 
 Fig.5. showing distribution of study population associated with chills and rigors 
6.DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
HEADACHE 
 
 
DIAGNOSIS 
  
  
  
HEADACHE  
TOTAL 
  
Yes No 
Malaria Count 29 13 42 
% within Diagnosis 69.0% 31.0% 100.0% 
  
Dengue 
  
Count 15 12 27 
% within Diagnosis 55.6% 44.4% 100.0% 
  
Typhoid 
  
Count 4 2 6 
% within Diagnosis 66.7% 33.3% 100.0% 
  
Leptospirosis 
  
Count 4 1 5 
% within Diagnosis 80.0% 20.0% 100.0% 
  
Sepsis 
  
Count 3 0 3 
% within Diagnosis 100.0% .0% 100.0% 
  
Unspecified viral fever 
  
  
Count 14 2 16 
% within Diagnosis 87.5% 12.5% 100.0% 
  
HIV 
  
Count 1 0 1 
% within Diagnosis 100.0% .0% 100.0% 
Total Count 70 30 100 
% within Diagnosis 70.0% 30.0% 100.0% 
Table 6. showing distribution of study population associated with headache 
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H
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U
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 70  out of 100 patients had fever associated with headache.  
29 out of this 70 patients were diagnosed with malaria.  
15 patients with dengue fever, 4 patients with typhoid fever, 4 patients with 
leptospirosis, 3 patients with sepsis and 14 patients with unspecified viral fever 
were having fever associated with headache. 
 
 
Fig.6. showing distribution of study population associated with headache 
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7.DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
GENERAL EXAMINATION FINDINGS 
 
 
                      
      DIAGNOSIS 
  
  
  
GENERAL EXAMINATION  
TOTAL 
  
NORMAL ANEMIA JAUNDICE 
  
Malaria 
Count 34 4 4 42 
% within Diagnosis 81.0% 9.5% 9.5% 100.0% 
  
Dengue 
  
Count 25 2 0 27 
% within Diagnosis 92.6% 7.4% .0% 100.0% 
  
Typhoid 
  
Count 5 1 0 6 
% within Diagnosis 83.3% 16.7% .0% 100.0% 
  
Leptospirosis 
  
Count 2 0 3 5 
% within Diagnosis 40.0% .0% 60.0% 100.0% 
  
Sepsis 
  
Count 0 1 2 3 
% within Diagnosis .0% 33.3% 66.7% 100.0% 
  
Unspecified viral fever 
Count 13 3 0 16 
% within Diagnosis 81.3% 18.8% .0% 100.0% 
  
HIV 
  
Count 0 1 0 1 
% within Diagnosis .0% 100.0% .0% 100.0% 
Total Count 79 12 9 100 
% within Diagnosis 79.0% 12.0% 9.0% 100.0% 
 
 
Table 7. showing distribution of study population associated with general examination findings 
 
12 % of the total patients had anemia and 9% of them had jaundice overall. 
4 out of 42 patients with malaria had anemia and jaundice on examination (9.5%). 
2 out of 27 patients with dengue fever were found to be anemic (7.4%). None had 
jaundice. 
33% of patients with sepsis had anemia and 67 % had jaundice. 
 
 
8.DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
JOINTPAIN 
 
 
 
           DIAGNOSIS 
  
  
  
          
          JOINT PAIN 
 
TOTAL 
  Yes No 
Malaria Count 8 34 42 
% within Diagnosis 19.0% 81.0% 100.0% 
  
Dengue 
  
Count 19 8 27 
% within Diagnosis 70.4% 29.6% 100.0% 
  
Typhoid 
  
Count 0 6 6 
% within Diagnosis .0% 100.0% 100.0% 
  
Leptospirosis 
  
Count 1 4 5 
% within Diagnosis 20.0% 80.0% 100.0% 
  
Sepsis 
 
Count 0 3 3 
% within Diagnosis .0% 100.0% 100.0% 
  
Unspecified viral fever 
  
Count 10 6 16 
% within Diagnosis 62.5% 37.5% 100.0% 
  
HIV 
  
Count 0 1 1 
% within Diagnosis .0% 100.0% 100.0% 
Total 
  
Count 38 62 100 
% within Diagnosis 38.0% 62.0% 100.0% 
 
Table 8. showing distribution of study population associated with joint pain 
 
 38% of the total study population presented with joint pain. 
19 % of patients with malaria had joint pain whereas 70.4% of patients with   
dengue fever had joint pain. 
62.5% of patients with unspecified viral fever had joint pain. 
 
 
 
 
Fig. 8. showing distribution of study population associated with joint pain 
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9.DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
NAUSEA AND VOMITING 
 
 
Table 9. showing distribution of study population associated with nausea and vomiting 
 
54 out of 100 patients had nausea and vomiting as one of the complaint in 
presenting illness. 
27 patients with malaria and 11 patients with dengue fever had nausea and 
vomiting. 
 
                    DIAGNOSIS 
  
  
  
NAUSEA,VOMIT  
TOTAL 
  
Yes No 
Malaria 
  
  
Count 27 15 42 
% within Diagnosis 64.3% 35.7% 100.0% 
  
Dengue 
  
Count 11 16 27 
% within Diagnosis 40.7% 59.3% 100.0% 
  
Typhoid 
  
Count 3 3 6 
% within Diagnosis 50.0% 50.0% 100.0% 
  
Leptospirosis 
  
Count 4 1 5 
% within Diagnosis    80.0% 20.0% 100.0% 
  
Sepsis 
  
Count 3 0 3 
% within Diagnosis 100.0% .0% 100.0% 
  
Unspecified viral fever 
  
Count 6 10 16 
% within Diagnosis 37.5% 62.5% 100.0% 
  
HIV 
  
Count 0 1 1 
% within Diagnosis .0% 100.0% 100.0% 
Total Count 54 46 100 
% within Diagnosis 54.0% 46.0% 100.0% 
  
Fig. 9. showing distribution of study population associated with nausea and vomiting 
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10.DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
ALTERED SENSORIUM 
 
DIAGNOSIS 
  
  
  
ALTERED 
SENSORIUM 
TOTAL 
  
Yes No 
Malaria Count 3 39 42 
% within Diagnosis 7.1% 92.9% 100.0% 
  
Dengue 
Count 1 26 27 
% within Diagnosis 3.7% 96.3% 100.0% 
  
Typhoid 
Count 0 6 6 
% within Diagnosis .0% 100.0% 100.0% 
  
Leptospirosis 
Count 0 5 5 
% within Diagnosis .0% 100.0% 100.0% 
  
Sepsis 
Count 2 1 3 
% within Diagnosis 66.7% 33.3% 100.0% 
  
Unspecified viral fever 
Count 2 14 16 
% within Diagnosis 12.5% 87.5% 100.0% 
  
HIV 
  
Count 0 1 1 
% within Diagnosis .0% 100.0% 100.0% 
Total 
  
Count 8 92 100 
% within Diagnosis 8.0% 92.0% 100.0% 
 
Table 10. showing distribution of study population associated with altered sensorium 
 
8 of the patients presented with altered sensorium in the study group.  
Out of which 3 of them had malaria, 2 had septicemia, 2 had unspecified viral 
fever and 1 was  diagnosed with dengue fever. 
  
Fig. 10. showing distribution of study population associated with altered sensorium 
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11.DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
HEPATOMEGALY AND SPLENOMEGALY 
 
 
                      
    DIAGNOSIS 
  
  
  
 
HEPATOMEGALY 
 
TOTAL 
  
Yes No 
Malaria 
  
Count 12 30 42 
% within Diagnosis 28.6% 71.4% 100.0% 
  
Dengue 
Count 1 26 27 
% within Diagnosis 3.7% 96.3% 100.0% 
  
Typhoid 
Count 4 2 6 
% within Diagnosis 66.7% 33.3% 100.0% 
  
Leptospirosis 
Count 5 0 5 
% within Diagnosis 100.0% .0% 100.0% 
  
Sepsis 
Count 1 2 3 
% within Diagnosis 33.3% 66.7% 100.0% 
  
Unspecified viral 
fever 
Count 2 14 16 
% within Diagnosis 12.5% 87.5% 100.0% 
  
HIV 
Count 1 0 1 
% within Diagnosis 100.0% .0% 100.0% 
Total 
  
Count 26 74 100 
% within Diagnosis 26.0% 74.0% 100.0% 
 
Table 11. showing distribution of study population associated with hepatomegaly 
 
26 patients in the total study group had hepatomegaly.  
Out of 26 patients with hepatomegaly, 12 pateints had malaria, 5 patients had 
leptospirosis, 4 patients had typhoid fever, 2 patients had unspecified viral fever, 1 
patient had dengue fever and 1 had HIV infection. 
 
  
Fig. 11. showing distribution of study population associated with hepatomegaly 
 
45 out of 100 study population had splenomegaly. 
29 out of 49 patients with splenomegaly had malaria. 
4 patients with typhoid fever and 4 patients with leptospirosis had leptospirosis. 
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12.DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
ASCITES 
 
 
 
   DIAGNOSIS 
  
  
  
ASCITES  
TOTAL 
  
Yes No 
Malaria 
  
Count 3 39 42 
% within Diagnosis 7.1% 92.9% 100.0% 
  
Dengue 
Count 0 27 27 
% within Diagnosis .0% 100.0% 100.0% 
  
Typhoid 
Count 0 6 6 
% within Diagnosis .0% 100.0% 100.0% 
  
Leptospirosis 
Count 2 3 5 
% within Diagnosis 40.0% 60.0% 100.0% 
  
Sepsis 
Count 2 1 3 
% within Diagnosis 66.7% 33.3% 100.0% 
  
Unspecified viral 
fever 
Count 0 16 16 
% within Diagnosis .0% 100.0% 100.0% 
  
HIV 
Count 0 1 1 
% within Diagnosis .0% 100.0% 100.0% 
Total 
  
Count 7 93 100 
% within Diagnosis 7.0% 93.0% 100.0% 
 
 
Table 12. showing distribution of study population associated with ascites 
 
 
7 patients in the study group had ascites. Out of which 3 patients had malaria, 2 
had leptospirosis and 2 had sepsis as their etiology. 
  
Fig. 12. showing distribution of study population associated with ascites 
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13 .DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
ANEMIA 
 
 
 DIAGNOSIS 
  
  
  
HB (G%)  
TOTAL <= 10 > 10 
Malaria 
  
Count 11 31 42 
% within Diagnosis 26.2% 73.8% 100.0% 
  
Dengue 
Count 6 21 27 
% within Diagnosis 22.2% 77.8% 100.0% 
  
Typhoid 
Count 1 5 6 
% within Diagnosis 16.7% 83.3% 100.0% 
  
Leptospirosis 
Count 3 2 5 
% within Diagnosis 60.0% 40.0% 100.0% 
  
Sepsis 
Count 2 1 3 
% within Diagnosis 66.7% 33.3% 100.0% 
 
Unspecified 
viral fever 
Count 4 12 16 
% within Diagnosis 25.0% 75.0% 100.0% 
 
HIV 
Count 1 0 1 
% within Diagnosis 100.0% .0% 100.0% 
Total 
  
Count 28 72 100 
% within Diagnosis 28.0% 72.0% 100.0% 
 
Table 13. showing distribution of study population associated with anemia 
 
28 patients out of the entire study group presented with anemia.  
Out of the 28 people, 11 had malaria as their diagnosis 
6 patients with dengue fever presented with anemia. 
4 patients with unspecified viral fever, 3 patients with leptospirosis, 2 patients with 
sepsis, 1 patient with HIV and 1 patient with typhoid presented with anemia. 
 Fig. 13. showing distribution of study population associated with anemia 
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 14 .DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
LEUKOCYTOSIS 
 
DIAGNOSIS 
  
  TLC TOTAL 
  < 11000 > 11000   
Malaria 
  
Count 35 7 42 
% within Diagnosis 83.3% 16.7% 100.0% 
  
Dengue 
 
Count 27 0 27 
% within Diagnosis 100.0% .0% 100.0% 
  
Typhoid 
Count 3 3 6 
% within Diagnosis 50.0% 50.0% 100.0% 
  
Leptospirosis 
Count 2 3 5 
% within Diagnosis 40.0% 60.0% 100.0% 
  
Sepsis 
Count 0 3 3 
% within Diagnosis .0% 100.0% 100.0% 
  
Unspecified viral 
fever 
Count 15 1 16 
% within Diagnosis 93.8% 6.3% 100.0% 
  
HIV 
Count 1 0 1 
% within Diagnosis 100.0% .0% 100.0% 
Total 
  
Count 83 17 100 
% within Diagnosis 83.0% 17.0% 100.0% 
 
Table 14. showing distribution of study population associated with leukocytosis 
 
17 patients out of study population had leukocytosis in this study. 
 Fig .14.. showing distribution of study population associated with leukocytosis 
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15 .DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
ELEVATED CREATININE 
 
 
 
DIAGNOSIS 
  
  CREATININE(MG/DL
) 
TOTAL 
  < 1 > 1   
Malaria 
  
Count 38 4 42 
% within Diagnosis 90.5% 9.5% 100.0% 
  
Dengue 
Count 27 0 27 
% within Diagnosis 100.0% .0% 100.0% 
  
Typhoid 
Count 5 1 6 
% within Diagnosis 83.3% 16.7% 100.0% 
  
Leptospirosis 
Count 4 1 5 
% within Diagnosis 80.0% 20.0% 100.0% 
  
Sepsis 
Count 0 3 3 
% within Diagnosis .0% 100.0% 100.0% 
  
Unspecified viral 
fever 
Count 15 1 16 
% within Diagnosis 93.8% 6.3% 100.0% 
  
HIV 
Count 1 0 1 
% within Diagnosis 100.0% .0% 100.0% 
Total 
 
Count 90 10 100 
% within Diagnosis 90.0% 10.0% 100.0% 
 
 Table 15. showing distribution of study population associated with elevated creatinine 
 
10 patients out of the entire study group had elevated creatinine.  
Malaria accounted for 4 of the cases.  
Elevated creatinine was found in 3 patients with sepsis. 1 patient of  typhoid fever, 
leptospirosis and unspecified viral fever had elevated creatinine each. 
  
 
 
Fig. 15. showing distribution of study population associated with elevated creatinine 
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16 .DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
HYPERBILIRUBINEMIA 
 
 
 
  DIAGNOSIS 
  
  SERUM 
BILIRUBIN(MG/DL) 
 
TOTAL 
    < 1 > 1 
Malaria 
 
Count 38 4 42 
% within Diagnosis 90.5% 9.5% 100.0% 
  
Dengue 
Count 27 0 27 
% within Diagnosis 100.0% .0% 100.0% 
  
Typhoid 
Count 5 1 6 
% within Diagnosis 83.3% 16.7% 100.0% 
  
Leptospirosis 
Count 3 2 5 
% within Diagnosis 60.0% 40.0% 100.0% 
  
Sepsis 
Count 0 3 3 
% within Diagnosis .0% 100.0% 100.0% 
  
Unspecified viral 
fever 
Count 16 0 16 
% within Diagnosis 100.0% .0% 100.0% 
  
HIV 
Count 1 0 1 
% within Diagnosis 100.0% .0% 100.0% 
Total 
  
Count 90 10 100 
% within Diagnosis 90.0% 10.0% 100.0% 
 
Table 16. showing distribution of study population associated with serum bilirubin 
 
 
10 patients out of the entire study population presented with jaundice.  
Out of the 10 patients having jaundice, 4 were diagnosed as having malaria, 3 were 
diagnosed as having sepsis. 
2 patients with leptospirosis had presented with jaundice and 1 patient with typhoid 
fever had jaundice. 
 
 Fig.16. showing distribution of study population associated with serum bilirubin 
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17 .DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
ELEVATED ALT LEVELS 
 
DIAGNOSIS 
  
  
  
ALT (IU/L) TOTAL 
  < 40 > 40 
 
Malaria 
Count 33 9 42 
% within Diagnosis 78.6% 21.4% 100.0% 
  
Dengue 
Count 24 3 27 
% within Diagnosis 88.9% 11.1% 100.0% 
  
Typhoid 
Count 3 3 6 
% within Diagnosis 50.0% 50.0% 100.0% 
  
Leptospirosis 
Count 3 2 5 
% within Diagnosis 60.0% 40.0% 100.0% 
  
Sepsis 
Count 0 3 3 
% within Diagnosis .0% 100.0% 100.0% 
  
Unspecified viral 
fever 
Count 14 2 16 
% within Diagnosis 87.5% 12.5% 100.0% 
  
HIV 
Count 0 1 1 
% within Alt (Iu/L) .0% 4.3% 1.0% 
 
Total 
Count 77 23 100 
% within Diagnosis 77.0% 23.0% 100.0% 
 
Table 17. showing distribution of study population associated with serum ALT 
 
23 patients out of the study group had ALT > 40 IU/L. 
9 patients with malaria and 3 patients with dengue, typhoid and sepsis each had 
elevated ALT. 
 Table 17. showing distribution of study population associated with serum ALT 
 
18 .DISTRIBUTION OF THE STUDY POPULATION ASSOCIATED WITH 
ELEVATED AST LEVELS 
 
  DIAGNOSIS 
  
  
  
            AST (IU/L)  
TOTAL 
  
< 40 > 40 
Malaria Count 33 9 42 
% within Diagnosis 78.6% 21.4% 100.0% 
  
Dengue 
Count 23 4 27 
% within Diagnosis 85.2% 14.8% 100.0% 
  
Typhoid 
Count 2 4 6 
% within Diagnosis 33.3% 66.7% 100.0% 
  
Leptospirosis 
Count 3 2 5 
% within Diagnosis 60.0% 40.0% 100.0% 
  
Sepsis 
Count 1 2 3 
% within Diagnosis 33.3% 66.7% 100.0% 
Unspecified viral 
fever 
Count 15 1 16 
% within Diagnosis 93.8% 6.3% 100.0% 
 
HIV 
Count 0 1 1 
% within Diagnosis .0% 100.0% 100.0% 
Total 
  
Count 77 23 100 
% within Diagnosis 77.0% 23.0% 100.0% 
 
Table 18. showing distribution of study population associated with serum AST 
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 23 patients out of the study group had AST > 40 IU/L. 
9 patients with malaria and 4 patients with dengue and typhoid each had elevated 
AST. 2 patients with leptospirosis and 2 patients with sepsis had AST >40IU/L. 
 
Fig. 18. showing distribution of study population associated with serum AST 
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19 .DISTRIBUTION OF THE STUDY POPULATION BASED ON THE 
REQUIREMENT OF BLOOD TRANSFUSION 
 
 
DIAGNOSIS 
  
  
  
BLOOD TRANSFUSION TOTAL 
No transfusion Fresh blood Whole blood, 
platelets 
  
Malaria Count 40 1 1 42 
% within Diagnosis 95.2% 2.4% 2.4% 100.0% 
  
Dengue 
Count 26 1 0 27 
% within Diagnosis 96.3% 3.7% .0% 100.0% 
  
Typhoid 
Count 6 0 0 6 
% within Diagnosis 100.0% .0% .0% 100.0% 
  
Leptospirosis 
Count 3 2 0 5 
% within Diagnosis 60.0% 40.0% .0% 100.0% 
  
Sepsis 
Count 0 2 1 3 
% within Diagnosis .0% 66.7% 33.3% 100.0% 
  
Unspecified viral 
fever 
Count 15 1 0 16 
% within Diagnosis 93.8% 6.3% .0% 100.0% 
  
HIV 
Count 1 0 0 1 
% within Diagnosis 100.0% .0% .0% 100.0% 
Total Count 91 7 2 100 
% within Diagnosis 91.0% 7.0% 2.0% 100.0% 
 
 
Table 19. showing distribution of study population according to need for blood transfusion 
 
 
 
 
 
A total of 9 patients had received transfusion of blood products. 
7 patients had received fresh whole blood alone and 2 of them had been transfused 
both fresh whole blood and platelets. 
The two patients who had received platelet transfusion were having sepsis and 
malaria. 
 
 
Fig. 19. showing distribution of study population according to need for blood transfusion 
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20. MEAN PLATELET COUNT IN THE STUDY POPULATION  
 
 
  NO. OF 
CASES 
MEAN 
PLATELET COUNT 
 
STD. 
DEVIATION 
Malaria 42 87928.57 29008.319 
Dengue 27 85770.37 30635.460 
Typhoid 6 91166.67 11617.516 
Leptospirosis 5 112000.00 18694.919 
Sepsis 3 49333.33 25006.666 
Unspecified viral fever 16 101562.50 24668.384 
HIV 1 8100.00 . 
 
Table 20. showing distribution of study population with mean platelet count and etiology 
 
The mean platelet count of patients with malaria was 87,929 ± 29,008 /cu.mm 
The mean platelet count of patients with dengue was 85,770 ± 30635/cu.mm 
The mean platelet count of patients with typhoid fever was 91167 ±11618/cu.mm 
The mean platelet count of patients with leptospirosis was 112000 ± 18695/cu.mm 
The mean platelet count of patients with sepsis was 49333 ± 25007/cu.mm 
The mean platelet count of patients with unspecified viral fever was 101562 ± 
24668/cu.mm 
The mean platelet count of patients with HIV was 8100/cu.mm 
 
 21. DISTRIBUTION OF THE STUDY POPULATION BASED ON THE 
THE GENDER 
 
  
FREQUENCY 
 
PERCENT 
Male 59 59.0 
Female 41 41.0 
Total 100 100.0 
 
Table 21. showing distribution of study population according to age 
 
Fig. 21. showing distribution of study population according to age 
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 22. DISTRIBUTION OF THE STUDY POPULATION BASED ON 
DEFINITE DIAGNOSIS 
 
 
  
FREQUENCY 
 
PERCENT 
Specified 84 84.0 
  
Unspecified viral fever 
16 16.0 
  
Total 
100 100.0 
 
Table 22. showing distribution of study population based on definite diagnosis 
 
A definitive diagnosis was made in 84 patients out of the 100 patients in the study 
group. 
 
Fig. 22. showing distribution of study population based on definite diagnosis 
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23. DISTRIBUTION OF THE STUDY POPULATION BASED ON THE 
SPECIES OF MALARIAL PARASITE 
 
  
FREQUENCY 
 
PERCENT 
Total malaria   
Vivax 29 29.0 
Falciparum 13 13.0 
 
Table 23. showing distribution of study population based the species of malarial parasite 
 
Out of 42 patients with malaria, 29 of them were plasmodium vivax positive and 
13 of them were having plasmodium falciparum infection. 
 
 
24. DISTRIBUTION OF THE STUDY POPULATION BASED ON THE 
MEAN PLATELET COUNT IN MALARIA 
 
 N MEAN STD. DEVIATION 
Vivax 28 92464.29 25611.748 
Falciparum 14 75384.62 32745.327 
Total 100 88969.00 29839.157 
 
Table 24. showing distribution of study population based on the mean platelet count in malaria 
 
The mean platelet count of patients with vivax malaria was 92,464 ± 
25,612/cu.mm 
The mean platelet count of patients with falciparum malaria was 75384 ± 
32,745/cu.mm 
 
25) DISTRIBUTION OF PATIENTS WITH BLEEDING MANIFESTATION 
 
NO. ETIOLOGY  PLATELET COUNT  
Cells/cumm 
1 Malaria 46000 
2 Sepsis 32000 
3 Malaria 56000 
4 Leptospirosis 88000 
5 Unspecified viral fever 130000 
6 Malaria 12000 
7 Sepsis 38000 
8 Dengue fever 42000 
9 Unspecified viral fever 98000 
10 Malaria 97000 
11 Malaria 71000 
  
Table 25. showing distribution of study population based on bleeding manifestation 
 Among patients who had bleeding manifestation (11 patients), 5 patients had 
malaria, 1 patient had dengue fever, 2 patients had sepsis, 1 patient had 
leptospirosis and 2 patients had unspecified viral fever. 
 
 
26) DISTRIBUTION OF PATIENTS WITH PLATELETS <20,000/CU.MM 
NO. ETIOLOGY PLATELET COUNT BLEEDING 
1 Malaria 12000 YES 
2 Dengue 12800 NO 
3 HIV 18000 NO 
 
Table 26. showing distribution of patients with platelets <20,000/cumm 
 
 
 
 
 
 
DISCUSSION 
 
THE INDIAN STUDY: 
                  This study was conducted by Nair PS, Jain A, Khanduri U, Kumar V 
in New Delhi for a period of one and half years. A total of 109 patients (76 males 
and 33 females) were admitted under Department of Medicine, St. Stephen’s 
Hospital from March 2002 to June 2003 and having the criteria similar to our 
study. 
                   In their study, Septicemia  [29 pts (26.6 %)] was the leading cause of 
fever-associated thrombocytopenia. Second common cause was typhoid fever 
followed by dengue fever [16 pts (14.7 %)], megaloblastic anemia, malaria and 
hematological malignancy in that order. Out of 109 patients 45 patients had 
thrombocytopenic signs accounting for 41.3%. Out of 45 patients spontaneous 
bleeding was seen in 31 patients. Out of 109 patients 62 patients (56.8 %) had 
platelet count between 50000- 100000, followed by 28 patients (25.7%) had count 
between 20000 – 50000. 
 
 
 
 
THE SRILANKAN STUDY : 
                           A retrospective study and analysis of patients admitted to a 
general medical unit with fever and thrombocytopenia as the primary reason for 
admission to the University Medical Unit, National Hospital of Sri Lanka over a 
period of 2 months (May 1, 2009 to the June 30, 2009) was done by Shiyana 
Ibrahim et al. 
                           Overall, 27% of patients had a platelet count below 50×10 
9
/L 
while three patients were found to have a count below 10×10
9
/L on admission. The 
mean platelet count at admission was 85.52  (range, 6–150) ×10 9/L. 
                            The lowest platelet count and highest hematocrit were seen on 
day 5. Bleeding manifestations were seen in 9(36%) of the 25 patients with a 
platelet count below 50×10
9
/ L. Bleeding manifestations were significantly more 
likely with lower platelet counts (P<0.008).  
                           However, there was no correlation between initial platelet counts 
and age, use of intravenous fluids, or length of hospital stay. 
 
 
THE COMPARISION BETWEEN VARIOUS STUDIES 
 
DISEASE 
CATEGORY 
NAIR STUDY PRESENT STUDY 
NO. OF 
CASES 
PERCENTAGE NO. OF 
CASES 
PERCENTAGE 
Septicemia 29 26..6 3 3 
Enteric fever 16 14.7 6 6 
Dengue fever 15 13.8 27 27 
Hematological 
conditions 
17 15.6 - - 
Malaria 10 9.2 42 42 
Others 20 18.3 22 22 
 
 
         In Nair’s study, the leading cause for fever with thrombocytopenia was 
septicemia. In our study the leading cause of febrile thrombocytopenia was 
malaria. Septicemia accounted for only 3% of cases in our study. 
         In Nair’s study, the 2nd leading cause for fever with thrombocytopenia was 
typhoid fever(among infections). In our study the 2
nd
 leading cause of febrile 
thrombocytopenia was dengue fever. Typhoid fever accounted for only 6% of 
cases in our study. 
         Dengue fever accounted for 13.8% of cases in Nair’s study wheras 27% of 
patients had dengue fever in our study. This could be due to seasonal and regional 
variations. 
         Patients in whom diagnosis could not be made was 20 patients (18.3%) in 
Nair’s study whereas in our study it was 16 patients (16%). 
 
 
 
 
BLEEDING 
MANIFESTATION 
NAIR STUDY PRESENT STUDY 
NO. OF 
CASES 
PERCENT
AGE 
NO. OF 
CASES 
PERCENTAGE 
Present 45 41.3 11 11 
Absent 64 58.7 89 89 
 
                 
     In Nair’s study, 41.3% had presented with bleeding manifestations wheras in 
our study only 11% of patients had bleeding manifestations. 
 
distribution of platelet 
count  in thousands 
NAIR STUDY PRESENT STUDY 
NO. OF 
CASES 
PERCENT
AGE 
NO. OF 
CASES 
PERCENTAGE 
< 20000 19 17.5 3 3.0 
20001-50000 28 25.7 10 10.0 
50001-100000 62 56.8 54 54.0 
100001-150000 - - 33 33.0 
 
In Nair’s study 17.5 % of patients presented with platelet count less than 
20000/cu.mm whereas in our study 3 patients had platelet count less than 
20000/cu.mm. 
In Nair’s study 25.7 of patients presented with platelet count 20001-
50000/cu.mm whereas in our study 10 patients had platelet count 20001-50000 
/cu.mm. 
          In our study, a total of 9 patients had received transfusion of blood products.          
7 patients had received fresh whole blood alone and 2 of them had been transfused 
both fresh whole blood and platelets.The two patients who had received platelet 
transfusion were having sepsis and malaria. 
 
 
 
 
 
 
 
 
 CONCLUSION 
1) Infections are one of the most common causes of thrombocytopenia. The 
leading cause of fever with thrombocytopenia in our study was Malaria. 
2) In malarial infection, the most common species was Plasmodium vivax followed 
by Plasmodium falciparum. 
3) Dengue fever was the second commonest cause of febrile thrombocytopenia 
4) There is no direct correlation between the severity of thrombocytopenia and the 
bleeding manifestation. 
4) Bleeding manifestation was present only in 11% of patients in the study. So in 
majority of patients, the thrombocytopenia was transient and asymptomatic.  
5) Prophylactic platelet transfusion may not be required in all cases of severe 
thrombocytopenia. It may be restricted to selected patients with bleeding 
manifestation or platelets <10,000/cumm which may indicate bone marrow 
compromise. 
6) Most of the patients in our study did not require platelet or blood transfusion and 
the platelet count significantly increased after the treatment of the underlying 
infection. 
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ABBREVIATIONS: 
TNF – Tumor Necrosis Factor 
IVIG – Intra Venous Immunoglobulin 
ALT – Alanine aminotransferase 
AST – Aspartate aminotransferase 
QBC – Quantitative Buffy Coat 
RBS –Random Blood Sugar 
BT – Bleeding Time 
P.Smear MP/MF – Peripheral smear for malarial parasite/microfilaria 
 
 
 
 
 
 
 
 
PROFORMA 
NAME : 
AGE : 
MARITAL STATUS : 
DOA  :  
DOD  :                                  
Occupation :    
CHIEF COMPLAINTS :    
 
PRESENTING COMPLAINTS :  
 
1. CHILLS & RIGORS  
2. MYALGIA  
3. RASHES  
4. JOINT PAIN/ 
5. SWELLING 
 
6. ORAL ULCERS  
7. PETECHIAE,  
8. PURPURA  
9. ECCHYMOSES  
10. GUM BLEEDING  
11. EPISTAXIS  
12. HEMOPTYSIS  
13. HE1MATEMESIS  
14. HEMATURIA  
15. MALENA  
16. MENORRHAGIA  
17. VOMITING  
18. DIARRHEA  
19. COUGH  
20. BREATHLESSNESS  
21. PALPITATION,CHEST 
PAIN 
 
22. ABDOMINAL PAIN  
23. PERIODICITY OF 
FEVER 
 
  
 
 
 
PAST HISTORY : 
 
 
 
 
 
 
 
 
 
PERSONAL / DRUG HISTORY : 
 
 
 
 
 
 
 
 
 
24. CALF PAIN  
25. HEADACHE  
26. SEIZURES  
27. SORE THROAT  
1. MALARIA  
2. TYPHOID  
3. BLEEDING DISORDERS   
4. LIVER DISEASE  
5. DIABETES  
6. HYPERTENSION  
7. LIVER DISEASE  
8. TUBERCULOSIS  
9. DENGUE  
10.D YSLIPIDEMIA  
HISTORY   
ASPIRIN/CLOPIDOGREL  
SMOKERS  
ALCOHOLICS  
ON EXAMINATION: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EXAMINATION  
ANEMIA  
ICTERUS  
CYANOSIS  
CLUBBING  
PEDAL EDEMA  
LYMPHANEDOPATHY  
SUBCONJUNCTIVAL HEMORRHAGE  
PETECHIAE/PURPURA/ECCHYMOSIS  
EPISTAXIS/GUM BLEED  
ORAL ULCERS  
ARTHRALGIA/ ARTHRITIS  
RASH  
TACHYCARDIA  
BRADYCARDIA  
HYPERTENSION  
HYPOTENSION  
TACHYPNEA  
CVS INVOLVEMENT  
RS INVOLVEMENT  
CNS INVOLVEMENT  
HEPATOMEGALY  
SPLENOMEGALY  
ASCITES  
FUNDAL INVOLVEMENT  
 INVESTIGATIONS : 
 
DATE       DATE    
Blood Sugar       Hb    
 Blood Urea       TC    
S. creatinine       DC    
 Serum Na       ESR    
Serum K       PLATELETS    
Serum HCO3       BT,CT    
Serum Cl       Peri.smear    
 
DATE    DATE   DATE  
S.bilirubin    Urine  sugar   S. Cholesterol  
Indirect 
bilirubin 
   Urine protein   S. TGL  
Direct bilirubin    Urine deposits   S.LDL  
TOTAL 
PROTEIN 
   Urine spot PCR   S.HDL  
ALT/AST    URINE C/S   BLOOD C/S  
SAP         
ALP         
 
DATE  DATE  
SMEAR - 
MP,MF 
 USG 
ABDOMEN 
 
WIDAL    
MSAT  CT   
LEPTOSPIROSIS 
IG 
   
HIV  XRAY  
Anti-HCV    
 
 
 
 
 
 
 
 
 
 
 
